PSTX — Poseida Therapeutics Share News
0.000.00%
Last trade - 00:00- $927.88m
- $755.94m
- $64.70m
Brief: Poseida Therapeutics Files For Mixed Shelf Of Up To $300 Mln
Poseida Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview
Poseida Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Poseida Therapeutics Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Astellas And Poseida Therapeutics Enter Collab And License Agreement To Develop Novel Allogeneic Cell Therapies
Brief: Poseida Therapeutics Announces Lineup Of Presentations At The American Society Of Gene And Cell Therapy Annual Meeting
Brief: Poseida Therapeutics Files For Shelf Of Up To 8.3 Mln Shares Of Common Stock
Brief: Poseida Therapeutics Announces FDA Orphan Drug Designation Granted To P-Bcma-Allo1 For The Treatment Of Multiple Myeloma
Poseida Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Poseida Therapeutics Provides Updates And Financial Results For The Fourth Quarter And Full Year 2023
RCS - Germfree - Germfree Announces Appointment of 4 Board Members
Brief: Poseida Therapeutics Highlights Recent Progress, Strategic Priorities And Anticipated 2024 Key Milestones
Brief: Poseida Therapeutics Presents Positive Early Results From Its Phase 1 Trial Of Allogeneic Car-T P-Bcma-Allo1 In Relapsed-Refractory Multiple Myeloma
CAR-T therapy developers fall amid U.S. FDA investigation
Brief: Poseida Therapeutics Announces Leadership Transition
Poseida Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Poseida Therapeutics Announces Strategic Investment By Astellas And Provides Business Update
Brief: Astellas And Poseida Therapeutics Announce Strategic Investment To Support Poseida's Commitment To Redefining Cancer Cell Therapy
Poseida Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview